Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3911 Sorrento Valley Blvd, Suite 110 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.ligand.com |
IR: | See website |
Key People | ||
Matthew Edward Korenberg President, Chief Operating Officer | Todd C. Davis Chief Executive Officer, Director | Octavio Espinoza Chief Financial Officer | Andrew Reardon Chief Legal Officer |
Business Overview |
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. It also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program. |
Financial Overview |
For the nine months ended 30 September 2023, Ligand Pharmaceuticals Inc revenues decreased 33% to $103.2M. Net income before extraordinary items totaled $35.6M vs. loss of $4.2M. Revenues reflect Captisol decrease of 68% to $24.5M, Contract revenue decrease of 30% to $17.3M. Net Income reflects Gain (loss) from short-term investments increase from $15.7M (expense) to $30.3M (income), Research and Development decrease of 50% to $13.7M (expense). |
Employees: | 76 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $880.07M as of Sep 30, 2023 |
Annual revenue (TTM): | $130.26M as of Sep 30, 2023 |
EBITDA (TTM): | $64.10M as of Sep 30, 2023 |
Net annual income (TTM): | $46.29M as of Sep 30, 2023 |
Free cash flow (TTM): | $79.34M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 17,435,958 as of Nov 6, 2023 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |